HOYA Lens Singapore Launches MiYOSMART iQTF, Advancing Myopia Control for Children

New-generation spectacle lens combines D.I.M.S. Technology with Triple Enhanced Design, with 9 out of 10 children showing no clinically relevant myopia progression* in the first 12 months of wear

SINGAPORE – Media OutRech Newswire – 8 September 2026 – HOYA Lens Singapore has launched MiYOSMART iQ^TF, introducing its most advanced myopia control spectacle lens and the latest evolution of its established MiYOSMART platform.

Newly launched in Singapore, MiYOSMART iQ^TF builds on MiYOSMART lenses, which feature Defocus Incorporated Multiple Segments (D.I.M.S.) Technology and are clinically proven to slow myopia progression by an average of 60%³. By combining D.I.M.S. Technology with the new Triple Enhanced Design (TED), MiYOSMART iQ^TF delivers greater myopia control effectiveness for children who need more.

In a randomised controlled clinical trial (RCT) of 196 schoolchildren in Hong Kong aged 4 to 12 years with myopia, 9 out of 10 children wearing MiYOSMART iQ^TF showed no clinically relevant myopia progression* in the first 12 months of wear^1,2.

The findings underscore the importance of managing myopia early in childhood, particularly as myopia can progress during a child's growing years. For parents, identifying and managing myopia early provides an opportunity to address its progression at a critical stage of a child's development.

This is particularly important for children who develop myopia at a younger age. The clinical findings for MiYOSMART iQ^TF demonstrated myopia control efficacy in children as young as four years old for the first time with D.I.M.S. Technology-based spectacle lenses¹. The research highlights the potential to manage early-onset myopia at a time when it can progress rapidly and the risk of longer-term impact is highest.

Myopia control spectacle lenses offer parents a non-invasive option for supporting their children's myopia management while providing the vision correction they need for everyday activities. MiYOSMART iQ^TF builds on this approach with an enhanced spectacle lens design developed specifically to deliver stronger myopia control outcomes.

"At HOYA Vision Care, we imagine a world without myopia. This milestone is truly a generational leap in myopia control and represents an important step toward the vision we are committed to shaping for children around the world. Until today, no trial conducted on a myopia control spectacle lens has shown this level of effectiveness in controlling the condition," said John Goltermann Lassen, CEO of HOYA Vision Care.

"Our mission is to improve life through vision by continuously raising the standard of care in myopia control, ensuring that thoughtful innovation and craftsmanship translate into meaningful clinical benefits for children and support eye care professionals' practice."

MiYOSMART iQ^TF builds on D.I.M.S. Technology with Triple Enhanced Design (TED), featuring three key enhancements designed to drive greater myopia control effectiveness in children²:

Activated: Defocus segments are positioned closer to the geometric centre of the spectacle lens and are intended to continuously activate a "sweet spot"⁴ on the near-peripheral retina — referred to by HOYA as the Smart Zone^† — identified by several studies as highly responsive to the myopic defocus signal that regulates myopia progression^5,6.

Powerful: Higher defocus power delivers a stronger myopic defocus signal.

Extended: An extended treatment zone provides more extensive coverage of the child's peripheral visual field, even with larger frames.

These enhancements build on the established D.I.M.S. Technology platform, with MiYOSMART iQ^TF representing the most advanced evolution of MiYOSMART, a technology backed by more than 100 peer-reviewed scientific publications⁷.

Options for Different Needs and Lifestyles

MiYOSMART iQ^TF is available in four options:

• Clear
  
• Clear with HOYA Full Control Coating
  
• Chameleon Photochromic
  
• Chameleon Photochromic with HOYA Full Control Coating
  

The Chameleon Photochromic options adapt to changing light conditions, darkening in sunlight to help reduce glare and fading back to clear indoors. This supports visual comfort as children move between classroom learning and outdoor activities, while providing protection against UV rays.

For added protection, HOYA Full Control Coating combines anti-reflective and scratch-resistant properties with blue light reduction, UV protection and an antibacterial treatment that helps limit bacterial growth on lens surfaces. Its water-, dirt- and dust-repellent properties also make the lenses easier to maintain during everyday wear.

With the introduction of MiYOSMART iQ^TF in Singapore, HOYA Vision Care continues to advance its myopia control portfolio through research, clinical evidence and spectacle lens innovation designed to support children and eye care professionals.

Learn more about MiYOSMART iQ^TF: https://www.hoyavision.com/sg/vision-products/myopia-management/miyosmart-iq/
Find an eyecare practitioner: https://www.hoyavision.com/sg/find-eye-care-practitioner/

Hear what other parents say about MiYOSMART: https://miyosmart.com.sg/

-END-

References:

*Outcomes for myopic children aged 4 to 12 years and may vary per age group and other parameters at the start of MiYOSMART iQTF treatment. Clinically relevant myopia progression is a change in cycloplegic spherical equivalent refraction of ≥-0.50D.

^†"Smart Zone" is a marketing term used by HOYA when referring to a near-peripheral retinal zone shown to respond to myopic defocus. It is not a standard clinical or scientific term.

1. Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D. K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA. https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941 (accessed date 03.04.2026).
   
2. HOYA data on file. HOYA MiYOSMART iQTF spectacle lens clinical outcomes. 04/2026.
   
3. Myopia progression (SER) by 59% and axial elongation (AL) decreased by 60% compared with those wearing SV lenses.Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019.
   
4. Swiatczak B, et al. Retinal "sweet spot" for myopia treatment. Sci Rep. 2024;14:26773.
   
5. HOYA data on file. MiYOSMART spectacle lens commercial data. 04/2026.
   
6. Smith III EL, Arumugam B, Hung LF, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020;177:32-40. DOI: 10.1016/j.visres. 2020.08.003.
   
7. HOYA Vision Care. Confidence Through Evidence. 2026. Available from: https://www.hoyavision.com/vision-products/miyosmart/evidences/. (Accessed: 16.04.2026).
   

Hashtag: #visioncare #myopia #HOYAvisioncare #myopiasingapore #childmyopia


https://www.hoyavision.com/sg/

The issuer is solely responsible for the content of this announcement.

HOYA Vision Care

For over 60 years, HOYA Vision Care has been a global leader in the eyeglass lens industry. The company is dedicated to providing innovative vision care solutions for every stage of a patient’s life. With a presence in over 50 countries, HOYA Vision Care has a leading position in myopia management category and a proven expertise in advanced lens designs, high performance photochromic technologies and high-quality AR coatings. HOYA Vision Care’s solid market portfolio includes HOYA, Vision Ease, SEIKO and PENTAX optical lenses, as well as innovative products such as MiYOSMART myopia control lenses for children, Hoyalux iD MySelf individualized progressive lenses and the Sensity range of photochromic lenses. The company employs over 20,000 employees worldwide with large scale production facilities in Asia, Europe, and the US and 38 local Rx laboratories globally. For more information, please visit https://www.hoyavision.com

About HOYA Corporation

Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company, and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of over 35,000 people. For more information, please visit www.hoya.com